Table 1 Baseline characteristics before propensity score matching.

From: Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study

 

Total (n = 1664)

Control (n = 1524)

GLP-1RA (n = 140)

P

Age, years

71.74 ± 11.25

72.70 ± 10.83

61.28 ± 10.39

 < .001

Male, n (%)

1140 (68.51)

1033 (67.78)

107 (76.43)

0.035

Hypertension, n (%)

1291 (77.63)

1183 (77.68)

108 (77.14)

0.885

Atrial fibrillation, n(%)

126(7.5)

119(7.81)

7(5.19)

0.233

Heart failue,n(%)

221(13.28)

182(11.94)

16(11.43)

0.551

Acute coronary syndrome,n(%)

331(19.89)

302(19.82)

29(20.71)

0.882

Diabetes duration, years

16.43 ± 5.60

16.52 ± 5.40

15.45 ± 7.40

0.096

Smokers, n (%)

741 (44.53)

658 (43.18)

83 (59.29)

 < .001

BMI, kg/m2

24.89 ± 7.57

24.74 ± 7.75

26.44 ± 5.20

0.011

HbA1c baseline, %

7.92 ± 1.59

7.84 ± 1.56

8.61 ± 1.67

 < .001

Fasting blood glucose, mmol/L

7.97 ± 3.38

7.88 ± 3.29

8.91 ± 4.05

 < .001

Total cholesterol, mmol/L

3.93 (3.24, 4.75)

3.92 (3.22, 4.71)

4.18 (3.43, 4.94)

0.007

HDL cholesterol, mmol/L

0.93 (0.78, 1.12)

0.93 (0.78, 1.12)

0.94 (0.79, 1.12)

0.484

LDL cholesterol, mmol/L

2.52 (1.89, 3.32)

2.48 (1.88, 3.31)

2.85 (2.15, 3.46)

0.005

Triglycerides, mmol/L

1.55 (1.14, 2.16)

1.54 (1.13, 2.15)

1.69 (1.23, 2.28)

0.054

Creatinine, μmol/L

78.00 (63.00, 99.00)

79.00 (64.00, 100.00)

72.00 (60.00, 88.00)

0.005

cTroponin I, ng/ml

0.01 (0.00, 0.18)

0.01 (0.00, 0.12)

0.04 (0.01, 1.64)

 < .001

Beta-blockers, n (%)

741 (44.53)

671 (44.03)

70 (50.00)

0.174

ACEI/ARB/ARNI, n (%)

938 (56.37)

850 (55.77)

88 (62.86)

0.106

Metformin, n (%)

1141 (68.57)

1045 (68.57)

96 (68.57)

1.000

Thiazolidinediones, n (%)

162 (9.74)

146 (9.58)

16 (11.43)

0.480

Insulins, n (%)

491 (29.51)

443 (29.07)

48 (34.29)

0.195

SGLT2 inhititors, n (%)

844 (50.72)

769 (50.46)

75 (53.57)

0.481

Statins, n (%)

1264 (75.96)

1150 (75.46)

114 (81.43)

0.114

Antiplatelet drugs, n (%)

1462 (87.76)

1334(87.53)

128 (91.43)

0.139

Anticoagulant drugs, n (%)

108 (6.49)

96 (6.3)

12 (8.57)

0.081

  1. For continuous variables, data are expressed as mean ± SD or median (Q1–Q3). For categorical variables, data are expressed as number (%). Significant p values are highlighted in bold. BMI body mass index; ACEI/ARB/ARNI angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor; SGLT2i sodium-glucose transport protein 2 inhibitors.
Back to article page